Research Analysts Set Expectations for SGMO Q1 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Sangamo Therapeutics in a note issued to investors on Tuesday, May 26th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will earn ($0.03) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at $0.00 EPS and Q4 2027 earnings at $0.00 EPS.

Several other research analysts have also recently issued reports on SGMO. Wall Street Zen cut Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. Zacks Research cut Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 16th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $5.50.

Sangamo Therapeutics Stock Performance

NASDAQ:SGMO opened at $0.19 on Wednesday. The stock has a fifty day moving average price of $0.23 and a two-hundred day moving average price of $0.36. The stock has a market capitalization of $76.68 million, a price-to-earnings ratio of -0.42 and a beta of 1.04. Sangamo Therapeutics has a 1 year low of $0.10 and a 1 year high of $0.77.

Institutional Trading of Sangamo Therapeutics

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in shares of Sangamo Therapeutics by 1,856.1% during the first quarter. Bank of America Corp DE now owns 1,838,390 shares of the biopharmaceutical company’s stock valued at $452,000 after acquiring an additional 1,744,406 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at $56,000. Invesco Ltd. boosted its stake in shares of Sangamo Therapeutics by 23.7% during the fourth quarter. Invesco Ltd. now owns 1,000,292 shares of the biopharmaceutical company’s stock valued at $420,000 after acquiring an additional 191,561 shares during the last quarter. Oracle Investment Management Inc. boosted its stake in shares of Sangamo Therapeutics by 3.1% during the fourth quarter. Oracle Investment Management Inc. now owns 1,035,742 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 31,018 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at $77,000. Institutional investors and hedge funds own 56.92% of the company’s stock.

Insider Activity at Sangamo Therapeutics

In related news, SVP Nathalie Dubois-Stringfellow sold 345,942 shares of the stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $0.26, for a total transaction of $89,944.92. Following the sale, the senior vice president owned 332,769 shares of the company’s stock, valued at $86,519.94. This trade represents a 50.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by insiders.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.